Allergan has acquired Topokine Therapeutics, a clinical-stage biotechnology company focused on topical medicines for fat reduction, for $85 million upfront and success-based development and sales milestones for XAF5, a topical agent in late-stage development for the treatment of steatoblepharon, also known as undereye bags.   XAF5 penetrates the skin and acts pharmacologically on fat cells to shrink undereye bags. In XOPH5-OINT-2, a Phase II randomized, placebo-controlled clinical trial, XAF5 ...